MSBase | Peer-reviewed journal articles

MSBase Registry research articles published in peer-reviewed journals

2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, van der Walt A, Butzkueven H, Terzi M, Gerlach O, Grand'Maison F, Foschi M, Surcinelli A, Barnett M, Lugaresi A, Onofrj M, Yamout B, Khoury SJ, Prevost J, Lechner-Scott J, Maimone D, Amato MP, Spitaleri D, Van Pesch V, Macdonell R, Cartechini E, de Gans K, Slee M, Castillo-Triviño T, Soysal A, Sanchez-Menoyo JL, Laureys G, Van Hijfte L, McCombe P, Altintas A, Weinstock-Guttman B, Aguera-Morales E, Etemadifar M, Ramo-Tello C, John N, Turkoglu R, Hodgkinson S, Besora S, Van Wijmeersch B, Fernandez-Bolaños R, Patti F; MSBase Study Group. Neurotherapeutics. 2025 Feb 17:e00552. doi: 10.1016/j.neurot.2025.e00552. Epub ahead of print. PMID: 39965993.

Explainable time-to-progression predictions in multiple sclerosis. D'hondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, Havrdova EK, Lugaresi A, Weinstock-Guttman B, Mrabet S, Lalive P, Kermode AG, Ozakbas S, Patti F, Prat A, Tomassini V, Roos I, Alroughani R, Gerlach O, Khoury SJ, van Pesch V, Sá MJ, Prevost J, Spitaleri D, McCombe P, Solaro C, van der Walt A, Butzkueven H, Laureys G, Sánchez-Menoyo JL, de Gans K, Al-Asmi A, Deri N, Csepany T, Al-Harbi T, Carroll WM, Rozsa C, Singhal B, Hardy TA, Ramanathan S, Peeters L, Vens C; MSBase Study Group. Comput Methods Programs Biomed. 2025 Feb 6;263:108624. doi: 10.1016/j.cmpb.2025.108624. Epub ahead of print. PMID: 39965473.

Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study. Müller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, Patti F, Grammond P, Buzzard K, Skibina O, Prat A, Girard M, Grand'Maison F, Alroughani R, Lechner-Scott J, Spitaleri D, Barnett M, Cartechini E, Sa MJ, Gerlach O, van der Walt A, Butzkueven H, Prevost J, Castillo-Triviño T, Yamout B, Khoury SJ, Yaldizli Ö, Derfuss T, Granziera C, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group. CNS Drugs. 2025 Feb 14. doi: 10.1007/s40263-025-01164-w. Epub ahead of print. PMID: 39953338.

2024

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network. Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Epub ahead of print. PMID: 39643429.

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD. Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M; for MSBase. Neurology. 2024 Dec 24;103(12):e209940. doi: 10.1212/WNL.0000000000209940. Epub 2024 Nov 19. PMID: 39561307.

The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study. Levitz D, Chao Foong Y, Sanfilippo P, et al. Therapeutic Advances in Neurological Disorders. 2024;17. doi:10.1177/17562864241278496

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. PMID: 39442037; PMCID: PMC11502106.

Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study. Kreiter D, Kalincik T, Hupperts R, Patti F, Spitaleri D, Foschi M, Surcinelli A, Maimone D, Yamout B, Khoury SJ, Lechner-Scott J, Ozakbas S, Gerlach O; MSBase Study Group. CNS Drugs. 2024 Sep 6. doi: 10.1007/s40263-024-01115-x. Epub ahead of print. PMID: 39242483.

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, Monif M; MSBASE study group. J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-334090. doi: 10.1136/jnnp-2024-334090. Epub ahead of print. PMID: 39231582.

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T. Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211. Epub ahead of print. PMID: 39087208.

Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study. De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, Laureys G, Van Wijmeersch B, Popescu V, Dhaene T, Deschrijver D, Waegeman W, De Baets B, Stock M, Horakova D, Patti F, Izquierdo G, Eichau S, Girard M, Prat A, Lugaresi A, Grammond P, Kalincik T, Alroughani R, Grand'Maison F, Skibina O, Terzi M, Lechner-Scott J, Gerlach O, Khoury SJ, Cartechini E, Van Pesch V, Sà MJ, Weinstock-Guttman B, Blanco Y, Ampapa R, Spitaleri D, Solaro C, Maimone D, Soysal A, Iuliano G, Gouider R, Castillo-Triviño T, Sánchez-Menoyo JL, Laureys G, van der Walt A, Oh J, Aguera-Morales E, Altintas A, Al-Asmi A, de Gans K, Fragoso Y, Csepany T, Hodgkinson S, Deri N, Al-Harbi T, Taylor B, Gray O, Lalive P, Rozsa C, McGuigan C, Kermode A, Sempere AP, Mihaela S, Simo M, Hardy T, Decoo D, Hughes S, Grigoriadis N, Sas A, Vella N, Moreau Y, Peeters L. PLOS Digit Health. 2024 Jul 25;3(7):e0000533. doi: 10.1371/journal.pdig.0000533. PMID: 39052668; PMCID: PMC11271865.

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D'Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A. J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518-7. Epub ahead of print. PMID: 38935148.

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Spelman T, Eichau S, Alroughani R, Ozakbas S, Khoury SJ, Patti F, Kubala Havrdova E, Boz C, Terzi M, Kuhle J, Grammond P, Lechner-Scott J, Gray O, Amato MP, Laureys G, Shaygannejad V, Hyde R, Wang H, Bozin I, Belviso N, Quan C, Zeng F, van der Walt A, Butzkueven H; MSBase Study Group. Mult Scler J Exp Transl Clin. 2024 May 25;10(2):20552173241247182. doi: 10.1177/20552173241247182. PMID: 38800132; PMCID: PMC11128181.

Leukocyte telomere length in multiple sclerosis: relationship between disability severity and pregnancy history. Zhong M, Salberg S, Sampangi S, van der Walt A, Butzkueven H, Mychasiuk R, Jokubaitis V. Mult Scler Relat Disord. 2024 Apr 10;86:105607. doi: 10.1016/j.msard.2024.105607. Epub ahead of print. PMID: 38631073.

Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study. Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, Khoury S, Lechner Scott J, Gerlach O, Lugaresi A, Maimone D, Surcinelli A, Grammond P, Kalincik T, Habek M, Willekens B, Macdonell R, Lalive P, Csepany T, Butzkueven H, Boz C, Tomassini V, Foschi M, Sánchez-Menoyo JL, Altintas A, Mrabet S, Iuliano G, Sa MJ, Alroughani R, Karabudak R, Aguera-Morales E, Gray O, de Gans K, van der Walt A, McCombe PA, Deri N, Garber J, Al-Asmi A, Skibina O, Duquette P, Cartechini E, Spitaleri D, Gouider R, Soysal A, Van Hijfte L, Slee M, Amato MP, Buzzard K, Laureys G. J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307. doi: 10.1136/jnnp-2023-333307. Epub ahead of print. PMID: 38569872.

Big Multiple Sclerosis Data network: an international registry research network. Glaser A, Butzkueven H, van der Walt A, Gray O, Spelman T, Zhu C, Trojano M, Iaffaldano P, Battaglia MA, Lucisano G, Vukusic S, Vukusic I, Casey R, Horakova D, Drahota J, Magyari M, Joensen H, Pontieri L, Elberling F, Klyve P, Mouresan EF, Forsberg L, Hillert J. J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303-6. Epub ahead of print. PMID: 38561543.

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6. Epub 2024 Mar 25. PMID: 38547883.

Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Kubala Havrdova E, Trneny M, Kozak T, Burman J, Macdonell R, Torkildsen Ø, Bø L, Lehmann AK, Sharrack B, Snowden J.. J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790. doi: 10.1136/jnnp-2023-332790. Epub ahead of print. PMID: 38538060.

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Lancet Child Adolesc Health. 2024 Mar 21:S2352-4642(24)00047-6. doi: 10.1016/S2352-4642(24)00047-6. Epub ahead of print. PMID: 38547883.

Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study. Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, Karabudak R, Yamout BI, Khoury SJ, Terzi M, Boz C, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Patti F, Altintas A, Mrabet S, Gouider R, Inshasi J, Shaygannejad V, Eichau S, Ward WL, Butzkueven H; MSBase Investigators. 2024 Apr 9;102(7):e208114. doi: 10.1212/WNL.0000000000208114. Epub 2024 Mar 6. PMID: 38447093.

No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry. Campagna MP, Havrdova EK, Horakova D, Izquierdo G, Matesanz F, Eichau S, Lechner-Scott J, Taylor BV, García-Sanchéz MI, Alcina A, van der Walt A, Butzkueven H, Jokubaitis VG. Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406. Epub ahead of print. PMID: 38511853

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. Foong YC, Merlo D, Gresle M, Buzzard K, Zhong M, Yeh WZ, Jokubaitis V, Monif M, Skibina O, Ozakbas S, Patti F, Grammond P, Amato MP, Kalincik T, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Lechner Scott J, Boz C, Sa MJ, Butzkueven H, van der Walt A, Zhu C; MSBASE study group. J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883. doi: 10.1136/jnnp-2023-332883. Epub ahead of print. PMID: 38453478.

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Butzkueven H, Kalincik T, Patti F, Slee M, Weinstock-Guttman B, Buzzard K, Skibina O, Alroughani R, Prat A, Girard M, Horakova D, Havrdova EK, Van der Walt A, Eichau S, Hyde R, Campbell N, Bodhinathan K, Spelman T; MSBase Investigators. Ther Adv Neurol Disord. 2024 Feb 26;17:17562864231221331. doi: 10.1177/17562864231221331. PMID: 38414723; PMCID: PMC10898303.

Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. Signori A, Ponzano M, Kalincik T, Ozakbas S, Horakova D, Kubala Havrdova E, Alroughani R, Patti F, Kuhle J, Izquierdo G, Eichau S, Yamout B, Khoury SJ, Karabudak R, Grammond P, Duquette P, Roos I, Butzkueven H, van der Walt A, Sormani MP J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603. doi: 10.1136/jnnp-2023-332603. Epub ahead of print. PMID: 38242680.

2023

Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP. Front Neurol. 2023 Dec 22;14:1274194. doi: 10.3389/fneur.2023.1274194. PMID: 38187157; PMCID: PMC10771327.

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, van Pesch V, Van Wijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Triviño T, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara C, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. J Med Econ. 2023 Dec 12:1-61. doi: 10.1080/13696998.2023.2293379. Epub ahead of print. PMID: 38085684.

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I. J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980-z. Epub ahead of print. PMID: 37768389.

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. PMID: 37437240; PMCID: PMC10186210.

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Yamout B, Altintas A, Gerlach O, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Hughes S, Sa MJ, Solaro C, Kappos L, Hodgkinson S, Slee M, Granella F, de Gans K, McCombe PA, Ampapa R, van der Walt A, Butzkueven H, Sánchez-Menoyo JL, Vucic S, Laureys G, Sidhom Y, Gouider R, Castillo-Trivino T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Al-Harbi TM, Csepany T, Sempere AP, Treviño Frenk I, Stuart EA, Kalincik T. J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499. doi: 10.1136/jnnp-2023-331499. Epub ahead of print. PMID: 37414534.

Risk of secondary progressive multiple sclerosis after early worsening of disability. Dzau W, Sharmin S, Patti F, Izquierdo G, Eichau S, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Ozakbas S, Gerlach O, Boz C, Grammond P, Terzi M, Amato MP, La Spitaleri D, Ramo-Tello C, Maimone D, Cartechini E, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Iuliano G, Soysal A, Kalincik T. J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748. doi: 10.1136/jnnp-2023-331748. Epub ahead of print. PMID: 37414538.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Triviño TC, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T. Brain. 2023 Jun 27:awad218. doi: 10.1093/brain/awad218. Epub ahead of print. PMID: 37369086.

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D'hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL. Mult Scler. 2023 Jun;29(7):875-883. doi: 10.1177/13524585231151951. Epub 2023 Feb 27. PMID: 36851894.

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. JAMA Neurol. 2023 Jun 12:e231625. doi: 10.1001/jamaneurol.2023.1625. Epub ahead of print. PMID: 37307006.

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Der Walt AV, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Morgado YB, Spitaleri D, Pesch VV, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H; MSBase Study Group. Neurodegener Dis Manag. 2023 Jun 7. doi: 10.2217/nmt-2023-0005. Epub ahead of print. PMID: 37287269. Epub ahead of print. PMID: 37273217

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, Alroughani R, Izquierdo G, Eichau S, Kuhle J, Patti F, Grand'Maison F, Hodgkinson S, Grammond P, Lechner-Scott J, Butler E, Prat A, Girard M, Duquette P, Macdonell RAL, Weinstock-Guttman B, Ozakbas S, Slee M, Sa MJ, Van Pesch V, Barnett M, Van Wijmeersch B, Gerlach O, Prevost J, Terzi M, Boz C, Laureys G, Van Hijfte L, Kermode AG, Garber J, Yamout B, Khoury SJ, Merlo D, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. JAMA Neurol. 2023 Jun 5:e231542. doi: 10.1001/jamaneurol.2023.1542. Epub ahead of print. PMID: 37273217

Disability accrual in primary and secondary progressive multiple sclerosis. Harding-Forrester S, Roos I, Nguyen AL, Malpas CB, Diouf I, Moradi N, Sharmin S, Izquierdo G, Eichau S, Patti F, Horakova D, Kubala Havrdova E, Prat A, Girard M, Duquette P, Grand'Maison F, Onofrj M, Lugaresi A, Grammond P, Ozakbas S, Amato MP, Gerlach O, Sola P, Ferraro D, Buzzard K, Skibina O, Lechner-Scott J, Alroughani R, Boz C, Van Pesch V, Cartechini E, Terzi M, Maimone D, Ramo-Tello C, Yamout B, Khoury SJ, La Spitaleri D, Sa MJ, Blanco Y, Granella F, Slee M, Butler E, Sidhom Y, Gouider R, Bergamaschi R, Karabudak R, Ampapa R, Sánchez-Menoyo JL, Prevost J, Castillo-Trivino T, McCombe PA, Macdonell R, Laureys G, Van Hijfte L, Oh J, Altintas A, de Gans K, Turkoglu R, van der Walt A, Butzkueven H, Vucic S, Barnett M, Cristiano E, Hodgkinson S, Iuliano G, Kappos L, Kuhle J, Shaygannejad V, Soysal A, Weinstock-Guttman B, Van Wijmeersch B, Kalincik T; MSBase investigators. J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726. doi: 10.1136/jnnp-2022-330726. Epub ahead of print. PMID: 37068931.

Comparative effectiveness in multiple sclerosis: A methodological comparison. Roos I, Diouf I, Sharmin S, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamou B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Ramo-Tello C, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sanchez-Menoyo JL, Laureys G, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Sempere AP, Trevino-Frenk I, Schepel J, Moore F, Malpas C, Kalincik T. Eur J Neurol. 2023 Apr;30(4):1014-1024. doi: 10.1111/ene.15706. Epub 2023 Feb 16. PMID: 36692895.

External validation of a clinical prediction model in multiple sclerosis Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, Yamout B, Khoury SJ, Turkoglu R, Karabudak R, Shalaby N, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T. Mult Scler. 2023 Feb;29(2):261-269. doi: 10.1177/13524585221136036. Epub 2022 Nov 30. PMID: 36448727.

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Hamdy S, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamout B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Kappos L, Ramo-Tello C, Cristiano E, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Slee M, Butler E, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sinnige LGF, Sanchez-Menoyo JL, Vucic S, Laureys G, Van Hijfte L, Khurana D, Macdonell R, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Perez Sempere A, Trevino-Frenk I, Schepel J, Moore F, Kalincik T. Eur J Neurol. 2023 Apr;30(4):1014-1024. doi: 10.1111/ene.15706. Epub 2023 Feb 16. PMID: 36692895.

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):23-30. doi: 10.1136/jnnp-2022-329987. Epub 2022 Sep 28. PMID: 36171104.

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. Spelman T, Horakova D, Ozakbas S, Alroughani R, Onofrj M, Kalincik T, Prat A, Terzi M, Grammond P, Patti F, Csepany T, Boz C, Lechner-Scott J, Granella F, Grand'Maison F, van der Walt A, Zhu C, Butzkueven H; MSBase Study Group. Mult Scler Relat Disord. 2023 Feb;70:104477. doi: 10.1016/j.msard.2022.104477. Epub 2022 Dec 23. PMID: 36746088.

2022

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity. Campagna MP, Xavier A, Lea RA, Stankovich J, Maltby VE, Butzkueven H, Lechner-Scott J, Scott RJ, Jokubaitis VG. Clin Epigenetics. 2022 Dec 30;14(1):194. doi: 10.1186/s13148-022-01397-2. PMID: 36585691; PMCID: PMC9805090.

External validation of a clinical prediction model in multiple sclerosis. Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, Yamout B, Khoury SJ, Turkoglu R, Karabudak R, Shalaby N, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T. Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036. Epub ahead of print. PMID: 36448727.

Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. Jokubaitis VG, Campagna MP, Ibrahim O, Stankovich J, Kleinova P, Matesanz F, Hui D, Eichau S, Slee M, Lechner-Scott J, Lea R, Kilpatrick TJ, Kalincik T, De Jager PL, Beecham A, McCauley JL, Taylor BV, Vucic S, Laverick L, Vodehnalova K, García-Sanchéz MI, Alcina A, van der Walt A, Havrdova EK, Izquierdo G, Patsopoulos N, Horakova D, Butzkueven H. Brain. 2022 Nov 30:awac449. doi: 10.1093/brain/awac449. Epub ahead of print. PMID: 36448302.

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H. Mult Scler. 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502. Epub ahead of print. PMID: 36433775.

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity. Simpson-Yap S, Pirmani A, Kalincik T, De Brouwer E, Geys L, Parciak T, Helme A, Rijke N, Hillert JA, Moreau Y, Edan G, Sharmin S, Spelman T, McBurney R, Schmidt H, Bergmann AB, Braune S, Stahmann A, Middleton RM, Salter A, Bebo B, Van der Walt A, Butzkueven H, Ozakbas S, Boz C, Karabudak R, Alroughani R, Rojas JI, van der Mei IA, Sciascia do Olival G, Magyari M, Alonso RN, Nicholas RS, Chertcoff AS, de Torres AZ, Arrambide G, Nag N, Descamps A, Costers L, Dobson R, Miller A, Rodrigues P, Prčkovska V, Comi G, Peeters LM. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 29;9(6):e200021. doi: 10.1212/NXI.0000000000200021. PMID: 36038263; PMCID: PMC9423711.

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. J Neurol Neurosurg Psychiatry. 2022 Oct 19:jnnp-2022-330104. doi: 10.1136/jnnp-2022-330104. Epub ahead of print. PMID: 36261289.

Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. Sharmin S, Malpas CB, Roos I, Diouf I, Alroughani R, Ozakbas S, Izquierdo G, Eichau S, Horakova D, Havrdova EK, Patti F, Terzi M, Boz C, Yamout B, Khoury SJ, Onofrj M, Lugaresi A, Altintas A, Prat A, Girard M, Duquette P, Sá MJ, La Spitaleri D, Sidhom Y, Gouider R, Mrabet S, Soysal A, Turkoglu R, Amato MP, Fragoso YD, Kalincik T. J Neurol Neurosurg Psychiatry. 2022 Sep 30: jnnp-2022-329713. doi: 10.1136/jnnp-2022-329713. Epub ahead of print. PMID: 36180218.

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network. J Neurol Neurosurg Psychiatry. 2022 Sep 28: jnnp-2022-329987. doi: 10.1136/jnnp-2022-329987. Epub ahead of print. PMID: 36171104.

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase; OFSEP. 2022 Aug 17:10.1212/WNL.0000000000201029. doi: 10.1212/WNL.0000000000201029. Epub ahead of print. PMID: 35977837.

Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Zhong M, van der Walt A, Stankovich J, Kalincik T, Buzzard K, Skibina O, Boz C, Hodgkinson S, Slee M, Lechner-Scott J, Macdonell R, Prevost J, Kuhle J, Laureys G, Van Hijfte L, Alroughani R, Kermode AG, Butler E, Barnett M, Eichau S, van Pesch V, Grammond P, McCombe P, Karabudak R, Duquette P, Girard M, Taylor B, Yeh W, Monif M, Gresle M, Butzkueven H, Jokubaitis VG. Mult Scler. 2022 May;28(6):958-969. doi: 10.1177/13524585211049986. Epub 2021 Oct 8. PMID: 34623947.

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. BMC Med Res Methodol. 2022 May 30;22(1):155. doi: 10.1186/s12874-022-01623-8. PMID: 35637426; PMCID: PMC9150358.

Confirmed disability progression as a marker of permanent disability in multiple sclerosis. Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, Alroughani R, Boz C, Shaygannejad V, van Pesch V, Cartechini E, Kappos L, Lechner-Scott J, Bergamaschi R, Turkoglu R, Solaro C, Iuliano G, Granella F, Van Wijmeersch B, Spitaleri D, Slee M, McCombe P, Prevost J, Ampapa R, Ozakbas S, Sanchez-Menoyo JL, Soysal A, Vucic S, Petersen T, de Gans K, Butler E, Hodgkinson S, Sidhom Y, Gouider R, Cristiano E, Castillo-Triviño T, Saladino ML, Barnett M, Moore F, Rozsa C, Yamout B, Skibina O, van der Walt A, Buzzard K, Gray O, Hughes S, Sempere AP, Singhal B, Fragoso Y, Shaw C, Kermode A, Taylor B, Simo M, Shuey N, Al-Harbi T, Macdonell R, Dominguez JA, Csepany T, Sirbu CA, Sormani MP, Butzkueven H, Kalincik T. Eur J Neurol. 2022 May 18. doi: 10.1111/ene.15406. Epub ahead of print. PMID: 35582938.

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study. Vitkova M, Diouf I, Malpas C, Horakova D, Kubala Havrdova E, Patti F, Ozakbas S, Izquierdo G, Eichau S, Shaygannejad V, Onofrj M, Lugaresi A, Alroughani R, Prat A, Larochelle C, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Butzkueven H, Buzzard K, Skibina O, Yamout BI, Karabudak R, Gerlach O, Lechner-Scott J, Maimone D, Bergamaschi R, Van Pesch V, Iuliano G, Cartechini E, José Sà M, Ampapa R, Barnett M, Hughes SE, Ramo-Tello CM, Hodgkinson S, Spitaleri DLA, Petersen T, Butler EG, Slee M, McGuigan C, McCombe PA, Granella F, Cristiano E, Prevost J, Taylor BV, Sãnchez-Menoyo JL, Laureys G, Van Hijfte L, Vucic S, Macdonell RA, Gray O, Olascoaga J, Deri N, Fragoso YD, Shaw C, Kalincik T; MSBase Study Group. Neurology. 2022 Jun 14;98(24):e2401-e2412. doi: 10.1212/WNL.0000000000200545. Epub 2022 Apr 11. PMID: 35410900; PMCID: PMC9231838.

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Boz C, Grand'Maison F, Bergamaschi R, Gerlach O, Sa MJ, Kappos L, Cartechini E, Lechner-Scott J, van Pesch V, Shaygannejad V, Granella F, Spitaleri D, Iuliano G, Maimone D, Prevost J, Soysal A, Turkoglu R, Ampapa R, Butzkueven H, Cutter G; for MSBase Study Group. Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577. Epub ahead of print. PMID: 35373638.

Multiple Sclerosis Relapses Following Cessation of Fingolimod. Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Kappos L, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T; MSBase Study Group. Clin Drug Investig. 2022 Apr;42(4):355-364. doi: 10.1007/s40261-022-01129-7. Epub 2022 Mar 18. PMID: 35303292; PMCID: PMC8989797.

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. PMID: 34921350; PMCID: PMC8866337.

2021

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Kenney R, Liu M, Patil S, Alroughani R, Ampapa R, Bergamaschi R, Boz C, Butzkueven H, Gomez JC, Cartechini E, Madueño SE, Ferraro D, Grand-Maison F, Granella F, Horakova D, Izquierdo Ayuso G, Kalincik T, Lizrova Preiningerova J, Lugaresi A, Onofrj M, Ozakbas S, Patti F, Sola P, Soysal A, Spitaleri DLA, Terzi M, Turkoglu R, van Pesch V, Saidha S, Thorpe LE, Galetta SL, Balcer LJ, Kister I, Spelman T; MSBase Study Group. J Neurol Sci. 2021 Nov 15;430:118067. doi: 10.1016/j.jns.2021.118067. Epub 2021 Sep 3. PMID: 34537678.

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pfleger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. CNS Drugs. 2021 Nov;35(11):1217-1232. doi: 10.1007/s40263-021-00860-7. Epub 2021 Sep 18. PMID: 34536228.

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik T, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D, Kyle K, Ramasamy DP, Zivadinov R. Neuroimage Clin. 2021;32:102802. doi: 10.1016/j.nicl.2021.102802. Epub 2021 Aug 24. PMID: 34469848; PMCID: PMC8408519.

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups. Neurology. 2021 Aug 31;97(9):e869-e880. doi: 10.1212/WNL.0000000000012354. Epub 2021 Jun 30. PMID: 34193589.

Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. Moradi N, Sharmin S, Malpas C, Ozakbas S, Shaygannejad V, Terzi M, Boz C, Yamout B, Turkoglu R, Karabudak R, Hamdy S, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T; MSBase Study Group. CNS Drugs. 2021 Oct;35(10):1097-1106. doi: 10.1007/s40263-021-00833-w. Epub 2021 Jun 23. PMID: 34164782.

Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. Comput Methods Programs Biomed. 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5. Erratum for: Comput Methods Programs Biomed. 2021 Sep;208:106180. PMID: 34749246.

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. Mult Scler Relat Disord. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8. PMID: 34116480.

The MSBase pregnancy, neonatal outcomes, and women’s health registry. Jokubaitis, VG. Skibina, O. Alroughani, R. Altintas, A. Butzkueven, H. Eichau, S. Fragoso, Y. Hellwig, K. Hughes, S. Rath, L. Van der Walt, A. Gray, O. Ther Adv Neurol Disord. (Apr 2021) 14: 1-8. doi: 10.1177/17562864211009104.

Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Yeh, W.Z. Widyastuti, P.A. Van der Walt, A. Stankovich, J. Havrdova, E. Horakova, D. Vodehnalova, K. Ozakbas, S. Eichau, S. Duquette, P. Kalincik, T. Patti, F. Boz, C. Terzi, M. Yamout, B.I. Lechner-Scott, J. Sola, P. Skibina, O.G. Barnett, M. Onofrj, M. José Sá, M. McCombe, P. Grammond, P. Ampapa, R. Grand'Maison, F. Bergamaschi, R. Spitaleri, D. Van Pesch, V. Cartechini, E. Hodgkinson, S. Soysal, A. Saiz, A. Gresle, M. Uher, T. Maimone, D. Turkoglu, R. Hupperts, R. Amato, MP. Granella, F. Oreja-Guevara, C. Altintas, A. Macdonell, R. Castillo-Trivino, T. Butzkueven, H. Alroughani, R. Jokubaitis, V.G. and the MSBase Study Group. doi: 10.1212/WNL.0000000000012084. [Online ahead of print – Apr 2021].

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. Butzkueven, H. Spelman, T. Horakova, D. Hughes, S. Solaro, C. Izquierdo, G. Havrdová, E.K. Grand'Maison, F. Prat, A. Girard, M. Hupperts, R. Onofrj, M. Lugaresi, A. Taylor, B. and the MSBase Study Group. Giovannoni, G. Kappos, L. Hauser, S.L. Montalban, X. Craveiro, L. Freitas, R. Model, F. Overell, J. Muros‐Le Rouzic, E. Sauter, A. Wang, Q. Wormser, D. Wolinsky, J.S. J. Neurol. doi: 10.1111/ene.14824. [Online ahead of print – Mar 2021].

Determinants of therapeutic lag in multiple sclerosis. Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Debouverie, M. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Edan, G. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Grammond, P. Ciron, J. Ruet, A. Ozakbas, S. De Seze, J. Louapre, C. Zephir, H. Sá, MJ. Sola, P. Ferraro, D. Labauge, P. Defer, G. Bergamaschi, R. Lebrun-Frenay, C. Boz, C. Cartechini, E. Moreau, T. Laplaud, D. Lechner-Scott, J. Grand'Maison, F. Gerlach, O. Terzi, M. Granella, F. Alroughani, R. Iuliano, G. Van Pesch, V. Van Wijmeersch, B. Spitaleri, D. Soysal, A. Berger, E. Prevost, J. Aguera-Morales, E. McCombe, P. Castillo Triviño, T. Clavelou, P. Pelletier, J. Turkoglu, R. Stankoff, B. Gout, O. Thouvenot, E. Heinzlef, O. Sidhom, Y. Gouider, R. Csepany, T. Bourre, B. Al Khedr, A. Casez, O. Cabre, P. Montcuquet, A. Wahab, A. Camdessanche, JP. Maurousset, A. Patry, I. Hankiewicz, K. Pottier, C. Maubeuge, N. Labeyrie, C. Nifle, C. Coles, A. Malpas, CB. Vukusic, S. Butzkueven, H. Kalincik, T. Mult Scler. doi: 10.1177/1352458520981300. [Online ahead of print – Jan 2021]. PMID: 33423618

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Kalincik, T. Diouf, I. Sharmin, S. Malpas, C. Spelman, T. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Jokubaitis, V. van der Walt, A. Grand'Maison, F. Sola, P. Ferraro, D. Shaygannejad, V. Alroughani, R. Hupperts, R. Terzi, M. Boz, C. Lechner-Scott, J. Pucci, E. Van Pesch, V. Granella, F. Bergamaschi. R. Spitaleri. D. Slee. M. Vucic. S. Ampapa, R. McCombe, P. Ramo-Tello, C. Prevost, J. Olascoaga, J. Cristiano, E. Barnett, M. Saladino, ML. Sanchez-Menoyo, JL. Hodgkinson, S. Rozsa, C. Hughes, S. Moore, F. Shaw, C. Butler, E. Skibina, O. Gray, O. Kermode, A. Csepany, T. Singhal, B. Shuey, N. Piroska, I. Taylor, B. Simo, M. Sirbu, CA. Sas, A. Butzkueven, H.; MSBase Study group. Neurology. (Feb 2021) 96(5): e783-e797. doi: 10.1212/WNL.0000000000011242.

2020

Treatment response score to glatiramer acetate or interferon beta-1a. Bovis, F. Kalincik, T. Lublin, F. Cutter, G. Malpas, C. Horakova, D. Havrdova, EK. Trojano, M. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Izquierdo, G. Eichau, S. Patti, F. Terzi, M. Grammond, P. Bergamaschi, R. Sola, P. Ferraro, D. Ozakbas, S. Iuliano, G. Boz, C. Hupperts, R. Grand'Maison, F. Oreja-Guevara, C. van Pesch, V. Cartechini, E. Petersen, T. Altintas, A. Soysal, A. Ramo-Tello, C. McCombe, P. Turkoglu, R. Butzkueven, H. Wolinsky, JS. Solaro, C. Sormani, MP. Neurology. doi: 10.1212/WNL.0000000000010991 [Online ahead of print – Oct 2020].

Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Onofrj, M. Lugaresi, A. Prat, A. Girard, M. Grammond, P. Sola, P. Ferraro, D. Ozakbas, S. Bergamaschi, R. Sá, MJ. Cartechini, E. Boz, C. Granella, F. Hupperts, R. Terzi, M. Lechner-Scott, J. Spitaleri, D. Van Pesch, V. Soysal, A. Olascoaga, J. Prevost, J. Aguera-Morales, E. Slee, M. Csepany, T. Turkoglu, R. Sidhom, Y. Gouider, R. Van Wijmeersch, B. McCombe, P. Macdonell, R. Coles, A. Malpas, CB. Butzkueven, H. Vukusic, S. Kalincik, T.; MSBase; OFSEP investigators. Brain. (Sept 2020) 143(9): 2742-2756. 10.1093/brain/awaa231

Association of Pregnancy With the Onset of Clinically Isolated Syndrome. Nguyen, A. Vodehnalova, K. KalinciK, T. Signori, A. Havrdova, E.K. Lechner-Scott, J. Skibina, O.G. Eastaugh, A. Taylor, L. Baker, J. McGuinn, N. Rath, L. Maltby, V. Sormani, MP. Butzkueven, H. Van der Walt, A. Horakova, D. Jokubaitis, V.G. JAMA Neurol. doi: 10.1001/jamaneurol.2020.3324. [Online ahead of print – Sept 2020].

Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. Lizak, N. Malpas,^,C.B. Sharmin, S.Havrdova, E.K. Horakova, D. Izquierdo, G.^, Eichau, S. Lugaresi, A.Duquette, P. Girard, M. Prat, A. Larochelle, C. Trojano, M. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Hupperts, R. Bergamaschi, R. Boz, C. Van Pesch, V. Spitaleri, D. Terzi, M. Kalincik, T. MSBase Study Group. JAMA Neurol. https://pubmed.ncbi.nlm.nih.gov/32716480/ [Online ahead of print – Jul 2020].

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Kunchok, A. Lechner-Scott, J. Granella, F. Trojano, M. Alroughani, R. Sola, P. Ferraro, D. Lugaresi, A. Onofrj, M. Ozakbas, S. Izquierdo, G. Grammond, P. Luis Sanchez-Menoyo, J. Van Wijmeersch, B. Boz, C. Pucci, E. McCombe, P. Grand'Maison, F. Spitaleri, D. Vucic, S. Hupperts, R. Jokubaitis, V. Sormani, MP. Butzkueven, H. Kalincik, T.; MSBase Study Group. Mult Scler. https://doi: 10.1177/1352458520936823. [Online ahead of print – Jul 2020].

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Le, M. Malpas, C. Sharmin, S. Horáková, D. Havrdova, E. Trojano, M. Izquierdo, G. Eichau, S. Ozakbas, S. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Larochelle, C. Alroughani, R. Bergamaschi, R. Sola, P. Ferraro, D. Grammond, P. Grand' Maison, F. Terzi, M. Boz, C. Hupperts, R. Butzkueven, H. Pucci, E. Granella, F. Van Pesch, V. Soysal, A. Yamout, BI. Lechner-Scott, J. Spitaleri, D. Ampapa, R. Turkoglu, R. Iuliano, G. Ramo-Tello, C. Sanchez-Menoyo, JL. Sidhom, Y. Gouider, R. Shaygannejad, V. Prevost, J. Altintas, A. Fragoso, YD. McCombe, PA. Petersen, T. Slee, M. Barnett, MH. Vucic, S. Van Der Walt, A. Kalincik, T. Mult Scler. https://doi/10.1177/1352458520926955 [Online ahead of print – Jun 2020].

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Lizak, N. Hodgkinson, S. Butler, E. Lechner-Scott, J. Slee, M. McCombe, PA. Shaw, C. Skibina, O. Vucic, S. Shuey, N. Barnett, MH. Parratt, J. Butzkueven, H. Jack, D. Fabris, J. Kalincik, T. Mult Scler. https://doi.org/10.1177/1352458520921087 [Online ahead of print – Jun 2020].

Early clinical markers of aggressive multiple sclerosis. Malpas, CB. Manouchehrinia, A. Sharmin, S. Roos, I. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Eichau, S. Bergamaschi, R. Sola, P. Ferraro, D. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Grand'Maison, F. Ozakbas, S. Van Pesch, V. Granella, F. Hupperts, R. Pucci, E. Boz, C. Sidhom, Y. Gouider, R. Spitaleri, D. Soysal, A. Petersen, T. Verheul, F. Karabudak, R. Turkoglu, R. Ramo-Tello, C. Terzi, M. Cristiano, E. Slee, M. McCombe, P. Macdonell, R. Fragoso, Y. Olascoaga, J. Altintas, A. Olsson, T. Butzkueven, H. Hillert, J. Kalincik, Brain. (May 2020) 143(5): 1400-1413. http://doi.org/10.1093/brain/awaa081

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observation cohort study. He, A. Merkel, B. Brown, JWL. Zhovits Ryerson, L. Kister, I. Malpas, CB. Sharmin, S. Horakova, D. Kubala Havrdova, E. Spelman, T. Izquierdo, G. Eichau, S. Trojano, M. Lugaresi, A. Hupperts, R. Sola, P. Ferraro, D. Lycke, J. Grand'Maison, F. Prat, A. Girard, M. Duquette, P. Larochelle, C. Svenningsson, A. Petersen, T. Grammond, P. Granella, F. Van Pesch, V. Bergamaschi, R. McGuigan, C. Coles, A. Hillert, J. Piehl, F. Butzkueven, H. Kalincik, T; MSBase study group. Lancet Neurol. (Apr. 2020) 19(4):307-316. https://doi.org/10.1016/S1474-4422(20)30067-3.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Kunchok, A. Malpas, C. Nytrova, P. Havrdova, EK. Alroughani, R. Terzi, M. Yamout, B. Hor, JY. Karabudak, R. Boz, C. Ozakbas, S. Olascoaga, J. Simo, M. Granella, F. Patti, F. McCombe, P. Csepany, T. Singhal, B. Bergamaschi, R. Fragoso, Y. Al-Harbi, T. Turkoglu, R. Lechner-Scott, J. Laureys, G. Oreja-Guevara, C. Pucci, E. Sola, P. Ferraro, D. Altintas, A. Soysal, A. Vucic, S. Grand'Maison, F. Izquierdo, G. Eichau, S. Lugaresi, A. Onofrj, M. Trojano, M. Marriott, M. Butzkueven, H. Kister, I. Kalincik, T. Mult Scler Relat Disord. http://dx.doi.org/10.1016/j.msard.2019.101868 [Epub ahead of print].

Risk of secondary progressive multiple sclerosis: A longitudinal study. Fambiatos, A. Jokubaitis, V. Horakova, D. Kubala Havrdova, E. Trojano, M. Prat, A. Girard, M. Duquette, P. Lugaresi, A. Izquierdo, G. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Alroughani, R. Terzi, M. Hupperts, R. Boz, C. Lechner-Scott, J. Pucci, E. Bergamaschi, R. Van Pesch, V. Ozakbas, S. Granella, F. Turkoglu, R. Iuliano, G. Spitaleri, D. McCombe, P. Solaro, C. Slee, M. Ampapa, R. Soysal, A. Petersen, T. Sanchez-Menoyo, JL. Verheu, F. Prevost, J. Sidhom, Y. Van Wijmeersch, B. Vucic, S. Cristiano, E. Saladino, ML. Deri, N. Barnett, M. Olascoaga, J. Moore, F. Skibina, O. Gray, O. Fragoso, Y. Yamout, B. Shaw, C. Singhal, B. Shuey, N. Hodgkinson, S. Altintas, A. Al-Harbi, T. Csepany, T. Taylor, B. Hughes, J. Jun, JK. van der Walt, A. Spelman, T. Butzkueven, H. Kalincik, T. Mult Scler. (Jan 2020) 26(1): 79-90 https://doi.org/10.1177/1352458519868990

2019

The MSBase Registry: Informing Clinical Practice. Kalincik, T. Butzkueven, H. Mult Scler. (Dec 2019) 25(14): 1828-1834 https://doi.org/10.1177/1352458519848965

Comparison of fingolimod, dimethyl fumarate and teriflunomide for Multiple Sclerosis. Kalincik, T. Kubala Havrdova, E. Horakova, D. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Grammond, P. Onofrj, M. Lugaresi, A. Ozakbas, S. Kappos, L. Kuhle, J. Terzi, M. Lechner-Scott, J. Boz, C. Grand'Maison, F. Prevost, J. Sola, P. Ferraro, D. Granella, F. Trojano, M, Bergamaschi, R. Pucci, E. Turkoglu, R. McCombe, P.A. Pesch, V.V. Van Wijmeersch, B. Solaro, C. Ramo-Tello, C. Slee, M. Alroughani, R. Yamout, B. Shaygannejad, V. Spitaleri, D. Sánchez-Menoyo, J.L. Ampapa, R. Hodgkinson, S. Karabudak, R. Butler, E. Vucic, S. Jokubaitis, V. Spelman, T. Butzkueven, H. J Neurol. Neurosurg Psychiatry. (Apr 2019) 90(4): 458-468. http://dx.doi.org/10.1136/jnnp-2018-319831

Incidence of pregnancy and disease-modifying therapy exposure trends in women with Multiple Sclerosis: A contemporary cohort study. Nguyen, A.L. Havrdova, E.K. Horakova, D. Izquierdo, G. Kalincik, T. van der Walt, A. Terzi, M. Alroughani, R. Duquette, P. Girard, M. Prat, A. Boz, C. Sola, P. Ferraro, D. Lugaresi, A. Lechner-Scott, J. Barnett, M. Grand'Maison, F. Grammond, P. Ramo-Tello, C. Turkoglu, R. McCombe, P. Pucci, E. Trojano, M. Granella, F. Spitaler, D. Van Pesch, V. Soysal, A. Oreja-Guevara, C. Verheul, F. Vucic, S. Hodgkinson, S. Slee, M. Ampapa, R. Prevost, J. Menoyo, J.L.S. Skibina, O. Solaro, C. Olascoaga, J. Shaw, C. Madsen, K.G. Naidoo, K. Hyde, R. Butzkueven, H. Jokubaitis, V.; MSBase Study Group. Mult Scler Relat Disord. (Feb 2019) 28:235-243. http://dx.doi.org/10.1016/j.msard.2019.01.003

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Lorscheider, J., J. Kuhle, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, R. Hupperts, P. Duquette, M. Girard, A. Prat, F. Grand’Maison, P. Grammond, P. Sola, D. Ferraro, M. Trojano, C. Ramo-Tello, J. Lechner-Scott, E. Pucci, C. Solaro, M. Slee, V. van Pesch, J.L.S. Menoyo, A van der Walt, H. Butzkueven, L. Kappos, T. Kalincik, on behalf of the MSBase Study Group. Eur J Neurol. (Feb 2019) 26(2): 363-370. http://dx.doi.org/10.1111/ene.13824.

Association of Initial Disease-Modifying Therapy with later conversion to Secondary Progressive Multiple Sclerosis. Brown, J.W.L. Coles, A. Horakova, D, Havrdova, E. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Trojano, M. Lugaresi, A. Bergamaschi, R. Grammond, P. Alroughani, R. Hupperts, R. McCombe, P. Van Pesch, V. Sola, P. Ferraro, D. Grand'Maison, F. Terzi, M. Lechner-Scott, J. Flechter, S. Slee, M. Shaygannejad, V. Pucci, E. Granella, F. Jokubaitis, V. Willis, M. Rice, C. Scolding, N. Wilkins, A. Pearson, O.R. Ziemssen, T. Hutchinson, M. Harding, K. Jones, J. McGuigan, C. Butzkueven, H. Kalincik, T. Robertson, N; MSBase Study Group. JAMA (Jan 2019) 15;321(2): 175-187 http://dx.doi.org/10.1001/jama.2018.20588

2018

Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis. Hughes, J., V. Jokubaitis, A. Lugaresi, R. Hupperts, G. Izquierdo, A. Prat, M. Girard, P. Duquette, F. Grand’Maison, P. Grammond, P. Sola, D. Ferraro, C. Ramo-Tello, M. Trojano, M. Slee, V. Shaygannejad, C. Boz, J. Lechner-Scott, V. Van Pesch, E. Pucci, C. Solaro, F. Verheul, M. Terzi, F. Granella, D. Spitaleri, R. Alroughani, J. K. Jun, A. Fambiatos, A. Van der Walt, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. JAMA Neurol. (Nov 2018) 1;75(11):1407-1415. http://dx.doi.org/10.1001/jamaneurol.2018.2109

Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. Min, M., T. Spelman, A. Lugaresi, C. Boz, D. Spitaleri, E. Pucci, F. Grand’Maison, F. Granella, G. Izquierdo, H. Butzkueven, J. L. Sanchez-Menoyo, M. Barnett, M. Girard, M. Trojano, P. Grammond, P. Duquette, P. Sola, R. Alroughani, R. Hupperts, S. Vucic, T. Kalincik, V. Van-Pesch and J. Lechner-Scott Mult Scler. (Oct 2018) 24(12): 1569-1577 http://dx.doi.org/10.1177/1352458518798147

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Kalincik, T., V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. Butler, M. Slee, A. Kermode, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueve, on behalf of the MSBase Study Group. Mult. Scler. (Oct 2018) 24(12):1617-1626. http://dx.doi.org/10.1177/1352458517728812

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Kister, I., T. Spelman, F. Patti, P. Duquette, M. Trojano, G. Izquierdo, A. Lugaresi, P. Grammond, P. Sola, D. Ferraro, F. Grand’Maison, R. Alroughani, M. Terzi, C. Boz, R. Hupperts, J. Lechner-Scott, L. Kappos, E. Pucci, S. Hodgkinson, C. Solaro, H. Butzkueven. J Neurol Sci (Aug 2018) 391: 72-76. http://dx.doi.org/10.1016/j.jns.2018.06.001

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Signori, A., G. Izquierdo, A. Lugaresi, R. Hupperts, F. Grand’Maison, P. Sola, D. Horakova, E. Havrdova, A. Prat, M. Girard, P. Duquette, C. Boz, P. Grammond, M. Terzi, B. Singhal, R. Alroughani, T. Petersen, C. Ramo, C. Oreja-Guevara, D. Spitaleri, V. Shaygannejad, H. Butzkueven, T. Kalincik, V. Jokubaitis, M. Slee, R. Fernández Bolaños , J. L. Sanchez-Menoyo, E. Pucci, F. Granella, J. Lechner-Scott, G. Iuliano, S. Hughes, R. Bergamaschi, B. Taylor, F. Verheul, M. Edite Rio, M.P. Amato, S.A. Sajedi, N. Majdinasab, V. Van Pesch, M.P. Sormani, M. Trojano. Mult Scler. (Apr 2018) 24(5): 642-652. http://dx.doi.org/10.1177/1352458517703800

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Fragoso, Y. D., T. Spelman, C. Boz, R. Alroughani, A. Lugaresi, S. Vucic, H. Butzkueven, M. Terzi, E. Havrdova, D. Horakova, F. Granella, J. Olascoaga, J. L. Sanchez-Menoyo, E. Pucci, M. Barnett, J. B. B. Brooks, J. Haartsen, on behalf of the MSBase Lymphopenia and Efficacy of Fingolimod Sub-Study Investigators. Mult Scler Relat Disord. (Jan 2018) 19: 105-108. http://dx.doi.org/10.1016/j.msard.2017.11.018

2017

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Kalincik, T, A. Manouchehrinia, L. Sobisek, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, R. Hupperts, F. Grand’Maison, E. Pucci, C. Boz, R. Alroughani, V. Van Pesch, J. Lechner-Scott, M. Terzi, R. Bergamaschi, G. Iuliano, F, Granella, D. Spitaleri, V. Shaygannejad, C. Oreja-Guevara, M. Slee, R. Ampapa, F. Verheul, P. McCombe, J. Olascoaga, M. P. Amato, S. Vucic, S. Hodgkinson, C. Ramo-Tello, S. Flechter, E. Cristiano, C. Rozsa, F. Moore, J. L. Sanchez-Menoyo, M. L. Saladino, M. Barnett, J. Hillert, H. Butzkueven, on behalf of the MSBase Study Group. Brain. (Sep 2017) 140(9): 2426-2443. http://dx.doi.org/10.1093/brain/awx185

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Lorscheider, J., V. G. Jokubaitis, T. Spelman, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, M. Trojano, P. Duquette, M. Girard, A. Prat, F. Grand'Maison, P. Grammond, E. Pucci, C. Boz, P. Sola, D. Ferraro, D. Spitaleri, J. Lechner-Scott, M. Terzi, V. Van Pesch, G. Iuliano, R. Bergamaschi, C. Ramo-Tello, F. Granella, C. Oreja-Guevara, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. Neurology. (Sep 2017) 89(10):1050-1059. http://dx.doi.org/10.1212/WNL.0000000000004330

Quantifying risk of early relapse in patients with demyelinating events: Prediction in clinical practice. Spelman, T., C. Meyniel, J.L. Rojas, A. Lugaresi, G. Izquierdo, F. Grand’Maison, C. Boz, R. Alroughani, E. Havrdova, D. Horakova, G. Iuliano, P. Duquette, M. Terzi, P. Grammond, R. Hupperts, J. Lechner-Scott, C. Oreja-Guevara, E. Pucci, F. Verheul, M. Fiol, V. Van Pesch, E. Cristiano, T. Petersen, F. Moore, T. Kalincik, V. Jokubaitis, M. Trojano, H. Butzkueven on behalf of the MSBasis (an MSBase Substudy) Investigators. Mult Scler. (Sep 2017) 23(10): 1346-1357. http://dx.doi.org/10.1177/1352458516679893

Incidence and prevalence of NMOSD in Australia and New Zealand. Bukhari, W., K. M. Prain, P. Waters, M. Woodhall, C. M. O’Gorman, L. Clarke, R. A. Silvestrini, C. S. Bundell, D. Abernethy, S. Bhuta, S. Blum, M. Boggild, K. Boundy, B. J. Brew, M. Brown, W. J. Brownlee, H. Butzkueven, W. M. Carroll, C. Chen, A. Coulthard, R. C. Dale, C. Das, K. Dear, M. J. Fabis-Pedrini, D. Fulcher, D. Gillis, S. Hawke, R. Heard, A. P. D. Henderson, S. Heshmat, S. Hodgkinson, S. Jimenez-Sanchez, T. Killpatrick, J. King, C. Kneebone, A. J. Kornberg, J. Lechner-Scott, M. W. Lin, C. Lynch, R. Macdonell, D. F. Mason, P. A. McCombe, M. P. Pender, J. A. Pereira, J. D. Pollard, S. W. Reddel, C. Shaw, J. Spies, J. Stankovich, I. Sutton, S. Vucic, M. Walsh, R. C. Wong, E. M. Yiu, M. H. Barnett, A. G. Kermode, M. P. Marriott, J. D. E. Parratt, M. Slee, B. V. Taylor, E. Willoughby, R. J. Wilson, A. Vincent, S. A. Broadly. J Neurosurg Psychiatry. (Aug 2017) 88(8):632-638. http://dx.doi.org/10.1136/jnnp-2016-314839

Prognostic indicators in pediatric clinically isolated syndrome. Iaffaldano, P., M. Simone, G. Lucisano, A. Ghezzi, G. Coniglio, V. Brescia Morra, F. Patti, A. Lugaresi, G. Izquierdo, R. Bergamaschi, J. A. Cabrera-Gomez, C. Pozzilli, E. Millefiorini, R. Alroughani, C. Boz, E. Pucci, G. B. Zimatore, P. Sola, G. Lus, D. Maimone, C. Avolio, E. Cocco, S.A. Sajedi, G. Costantino, P. Duquette, V. Shaygannejad, T. Petersen, R. Fernández Bolaños, D. Paolicelli, C. Tortorella, T. Spelman, L. Margari, M.P. Amato, G. Comi, H. Butzkueven, M. Trojano, on behalf of the Italian iMedWeb Registry and the MSBase Registry. Ann Neurol. (May 2017) 81(5):729-739. http://dx.doi.org/10.1002/ana.24938

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Kalincik, T., J.W.L. Brown, N. Robertson, M. Willis, N. Scolding, C.M. Rice, A. Wilkins, O. Pearson, T. Ziemssen, M. Hutchinson, C. McGuigan, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, R. Alroughani, E. Pucci, P. Sola, R. Hupperts, J. Lechner-Scott, M. Terzi, V. Van Pesch, C. Rozsa, F. Grand’Maison, C. Boz, F. Granella, M. Slee, D. Spitaleri, J. Olascoaga, R. Bergamaschi, F. Verheul, S. Vucic, P. McCombe, S. Hodgkinson, J.L. Sanchez-Menoyo, R. Ampapa, M. Simo, T. Csepany, C. Ramo, E. Cristiano, M. Barnett, H. Butzkueven, A. Coles on behalf of the MSBase Study Group. Lancet Neurol. (Apr 2017) 16(4):271-281. http://dx.doi.org/10.1016/S1474-4422(17)30007-8

Data quality evaluation for observational multiple sclerosis registries. Kalincik, T., J. Kuhle, E. Pucci, J. I. Rojas, M. Tsolaki, C. A. Sirbu, M. Slee, H. Butzkueven, on behalf of the MSBase Scientific Leadership Group and MSBase Study Group. Mult Scler. (Apr 2017) 23(5):647-655. http://dx.doi.org/10.1177/1352458516662728

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Lizak, N., A. Lugaressi, R. Alroughani, J. Lechner-Scott, M. Slee, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, P. Grammond, R. Hupperts, F. Grand’Maison, P. Sola, E. Pucci, R. Bergamaschi, C. Oreja-Guevara, V. Van Pesch, C. Ramo, D. Spitaleri, G. Iuliano, C. Boz, F. Granella, J. Olascoaga, F. Verheul, C. Rozca, E. Cristiano, S. Flechter, S. Hodgkinson, M.P. Amato, N. Deri, V. Jokubaitis, T. Spelman, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Mar 2017) 88(3):196-203. http://dx.doi.org/10.1136/jnnp-2016-313976

Contribution of different relapse phenotypes to disability in multiple sclerosis. Stewart, T., T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, P. Sola, V. Shaygannejad, R. Hupperts, R. Alroughani, C. Oreja-Guevara, E. Pucci, C. Boz, J. Lechner-Scott, R. Bergamaschi, V. Van Pesch, G. Iuliano, C. Ramo, B. Taylor, M. Slee, D. Spitaleri, F. Granella, F. Verheul, P. McCombe, S. Hodgkinson, M. P. Amato, S. Vucic, O. Gray, E. Cristiano, M. Barnett, J. L. Sanchez- Menoyo, E. van Munster, M. L. Saladino, J. Olascoaga, J. Prevost, N. Deri, C. Shaw, B. Singhal, F. Moore, C. Rozsa, N. Shuey, O. Skibina, I. Kister, T. Petkovska-Boskova, R. Ampapa, A. Kermode, H. Butzkueven, V. Jokubaitis, T. Kalincik on behalf of the MSBase Study Group. Mult Scler. (Feb 2017) 23(2):266-276. http://dx.doi.org/10.1177/1352458516643392

2016

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Tao, C., S. Simpson Jr, I. van der Mei, L. Blizzard, E. Havrdova, D. Horakova, V. Shaygannejad, A. Lugaresi, G. Izquierdo, M. Trojano, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, R. Alroughani, M. Terzi, C. Oreja-Guevara, S.A. Sajedi, G. Iuliano, P. Sola, J. Lechner-Scott, V. Van Pesch, E. Pucci, R. Bergamaschi, M. Barnett, C. Ramo, B. Singhal, D. LA Spitaleri, M. Slee, F. Verheul, R. Fernández Bolaños, M.P. Amato, E. Cristiano, F. Granella, S. Hodgkinson, M. Fiol, O. Gray, P. McCombe, M.L. Saladino, J.L. Sanchez Menoyo, N. Shuey, S. Vucic, C. Shaw, N. Deri, W. Oleschko-Arruda, H. Butzkueven, T. Spelman, B.V. Taylor on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Dec 2016) 87(12):1343-1349. http://dx.doi.org/10.1136/jnnp-2016-314013

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Oct 2016) 87(10):1133-7. http://dx.doi.org/10.1136/jnnp-2016-313760

Defining secondary progressive multiple sclerosis. Lorscheider , J., K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J. Lechner-Scott, R. Bergamaschi, C. Oreja-Guevara, G. Iuliano, V. Van Pesch, F. Granella, C. Ramo-Tello, D. Spitaleri, T. Petersen, M. Slee, F. Verheul, R. Ampapa, MP. Amato, P. McCombe, S. Vucic, JL. Sanchez Menoyo, E. Cristiano, MH. Barnett, S. Hodgkinson, J. Olascoaga, ML. Saladino, O. Gray, C. Shaw, F. Moore, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. Brain. (Sep 2016) 139(Pt 9):2395-405. http://dx.doi.org/10.1093/brain/aww173

Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. Ann Neurol. (Jul 2016) 80(1):89-100. http://dx.doi.org/10.1002/ana.24682

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Jokubaitis, V.G., T. Spelman, T. Kalincik, J. Lorscheider, E. Havrdova, D. Horakova, P. Duquette, M. Girard, A. Prat, G. Izquierdo, P. Grammond, V. Van Pesch, E. Pucci, F. Grand’Maison, R. Hupperts, F. Granella, P. Sola, R. Bergamaschi, G. Iuliano, D. Spitaleri, C. Boz, S. Hodgkinson, J. Olascoaga, F. Verheul, D. Paolicelli, H. Butzkueven, A. Lugaresi and M. Trojano, for the MSBase Study Group. Neurol Clin Pract. (Apr 2016) 6(2):102-115. http://dx.doi.org/10.1212/CPJ.0000000000000227

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman, T., L. Mekhael, T. Burke, H. Butzkueven, S. Hodgkinson, E. Havrdova, D. Horakova, P. Duquette, G. Izquierdo, F. Grand’Maison, P. Grammond, M. Barnett, J. Lechner-Scott, R. Alroughani, M. Trojano, A. Lugaresi, F. Granella, E. Pucci and S. Vucic on behalf of the MSBase Study Group. Eur J Neurol. (Apr 2016) 23(4):729-736. http://dx.doi.org/10.1111/ene.12929

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Warrender-Sparkes, M., T. Spelman, G. Izquierdo, M. Trojano, A. Lugaresi, F. Grand’Maison, E. Havrdova, D. Horakova, C. Boz, C. Oreja-Guevara, R. Alroughani, G. Iuliano, P. Duquette, M. Girard, M. Terzi, R. Hupperts, P. Grammond, T. Petersen, R. Fernández Bolaños, M. Fiol, E. Pucci, J. Lechner-Scott, F. Verheul, E. Cristiano, V. Van Pesch, T. Petkovska-Boskova, F. Moore, I. Kister, R. Bergamaschi, M. L. Saladino, M. Slee, M. Barnett, M. P. Amato, C. Shaw, N. Shuey, C. Young, O. Gray, L. Kappos, H. Butzkeven, T. Kalincik and V. Jokubaitis, on behalf of the MSBase study group. Mult Scler. (Apr 2016) 22(4):520-532. http://dx.doi.org/10.1177/1352458515594041

2015

Defining reliable disability outcomes in multiple sclerosis. Kalincik, T., G. Cutter, T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Hupperts, C. Oreja-Guevara, C. Boz, E. Pucci, R. Bergamaschi, J. Lechner-Scott, R. Alroughani, V. Van Pesch, G. Iuliano, R. Fernández Bolaños, C. Ramo, M. Terzi, M. Slee, D. Spitaleri, F. Verheul, E. Cristiano, J. L. Sánchez-Menoyo, M. Fiol, O. Gray, J. A. Cabrera-Gomez, M. Barnett, H. Butzkueven, on behalf of the MSBase study group. Brain. (Nov 2015) 138 (Pt 11):3287-98. http://dx.doi.org/10.1093/brain/awv258

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik, T., V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, A. Lugaresi, C. Oreja-Guevara, R. Bergamaschi, R. Hupperts, F. Grand’Maison, E. Pucci, V. Van Pesch, C. Boz, G. Iuliano, R. Fernández Bolaños, S. Flechter, D. Spitaleri, E. Cristiano, F. Verheul, J. Lechner-Scott, M. P. Amato, J. A. Cabrera-Gomez, M. L. Saladino, M. Slee, F. Moore, O. Gray, M. Paine, M. Barnett, E. Havrdova, D. Horakova, T. Spelman, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. Mult Scler. (Aug 2015) 21(9):1159-71. http://dx.doi.org/10.1177/1352458514559865

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Rojas, J. I., L. Patrucco, M. Trojano, A. Lugresi, G. Izquierdo, H. Butzkueven, V. Jokubaitis, P. Duquette, M. Girard, F. Grand’Maison, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. Van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, R. Fernández Bolaños, D. Poehlau, M. L. Saladino, L. Den Braber-Moerland, N. Deri, W. Oleschko-Arruda, J. A. Cabrera-Gomez, M. Paine, N. Vella, I. Kister, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, E. A. Bacile Bacile, V. Santiago, E. Cristiano, on behalf of the MSBase study group. Mult Scler J Exp Transl Clin. (Aug 2015). http://dx.doi.org/10.1177/2055217315600193

Male Sex is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. Ribbons, K. A., P. McElduff, C. Boz, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, R. Hupperts, P. Grammond, C. Oreja-Guevara, T. Petersen, R. Bergamaschi, G. Giuliani, M. Barnett, V. van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaños, M. L. Saladino, M. E. Rio, J. Cabrera-Gomez, H. Butzkueven, E. van Munster, L. Den Braber-Moerland, D. La Spitaleri, A. Lugaresi, V. Shaygannejad, O. Gray, N. Deri, R. Alroughani and J. Lechner-Scott. PLoS One. (Jun 2015) 10(6):e0122686. http://dx.doi.org/10.1371/journal.pone.0122686

BREMSO: a simple score to predict early the natural course of multiple sclerosis. Bergamaschi, R., C. Montomoli, G. Mallucci, A. Lugaresi, G. Izquierdo, F. Grand’Maison, P. Duquette, V. Shaygannejad, R. Alroughani, P. Grammond, C. Boz, G. Iuliano, C. Zwanikken, T. Petersen, J. Lechner-Scott, R. Hupperts, H. Butzkueven, E. Pucci, C. Oreja-Guevara, E. Cristiano, M. P. Pia Amato, E. Havrdova, R. Fernández Bolaños, T. Spelman and M. Trojano. Eur J Neurol. (Jun 2015) 22(6):981-9. http://dx.doi.org/10.1111/ene.12696

Predictors of disability worsening in clinically isolated syndrome. Jokubaitis, V. J., T. Spelman, T. Kalincik, G. Izquierdo, F. Grand’Maison, P. Duquette, M. Girard, A. Lugaresi, P. Grammond, R. Hupperts, J. Cabrera-Gomez, C. Oreja-Guevara, C. Boz, G. Giuliani, R. Fernández Bolaños, G. Iuliano, J. Lechner-Scott, F. Verheul, V. Van Pesch, T. Petkovska-Boskova, M. Fiol, F. Moore, E. Cristiano, R. Alroughani, R. Bergamaschi, M. Barnett, M. Slee, N. Vella, J. Herbert, C. Shaw, M. L. Saladino, M. P. Amato, D. Liew, D. Paolicelli, H. Butzkueven and M. Trojano, on behalf of the MSBasis Study Group. Ann Clin Transl Neurol. (May 2015) 2(5):479-91. http://dx.doi.org/10.1002/acn3.187

Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman, T., T. Kalincik, A. Zhang, F. Pellegrini, H. Wiendl, L. Kappos, L. Tsvetkova, S. Belachew, R. Hyde, F. Verheul, F. Grand-Maison, G. Izquierdo, P. Grammond, P. Duquette, A. Lugaresi, J. Lechner-Scott, C. Oreja-Guevara, R. Hupperts, T. Petersen, M. Barnett, M. Trojano and H. Butzkueven, on behalf of the MSBase Investigators and the TOP Investigators. Ann Clin Transl Neurol. (Apr 2015) 2(4):373-87. http://dx.doi.org/10.1002/acn3.180

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He, A., T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, A. Lugaresi, G. Izquierdo, P. Grammond, P. Duquette, M. Girard, E. Pucci, G. Iuliano, R. Alroughani, C. Oreja-Guevara, R. Fernández Bolaños, F. Grand’Maison, P. Sola, D. Spitaleri, F. Granella, M. Terzi, J. Lechner-Scott, V. Van Pesch, R. Hupperts, J. L. Sánchez-Menoyo, S. Hodgkinson, C. Rozsa, F. Verheul, H. Butzkueven, T. Kalincik; for the MSBase Study Group. JAMA Neurol. (Apr 2015) 72(4):405-13. http://dx.doi.org/10.1001/jamaneurol.2014.4147

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik, T., D. Horakova, T. Spelman, V. Jokubaitis, M. Trojano, A. Lugaresi, G. Izquierdo, C. Rozsa, P. Grammond, R. Alroughani, P. Duquette, M. Girard, E. Pucci, J. Lechner-Scott, M. Slee, R. Fernández Bolaños, F. Grand’Maison, R. Hupperts, F. Verheul, S. Hodgkinson, C. Oreja-Guevara, D. Spitaleri, M. Barnett, M. Terzi, R. Bergamaschi, P. McCombe, J. Sanchez-Menoyo, M. Simo, T. Csepany, G. Rum, C. Boz, E. Havrdova, H. Butzkueven; on behalf of the MSBase Study Group. Ann Neurol. (Mar 2015) 77(3):425-35. http://dx.doi.org/10.1002/ana.24339

2014

Seasonal variation of relapse rate in multiple sclerosis is latitude-dependent. Spelman, T., O. Gray, M. Trojano, T. Petersen, G. Izquierdo, A. Lugaresi, R. Hupperts, R. Bergamaschi, P. Duquette, P. Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja-Guevara, M. Barnett, F. Grand’Maison, M. E. Rio, J. Lechner-Scott, V. Van Pesch, R. Fernández Bolaños, S. Flechter, L. Den Braber-Moerland, G. Iuliano, M. P. Amato, M. Slee, E. Cristiano, M.L. Saladino, M. Paine, N. Vella, K. Kasa, N. Deri, J. Herbert, F. Moore, T. Petkovska-Boskova, R. Alroughani, A. Savino, C. Shaw, S. Vucic, V. Santiago, E. A. Bacile, E. Skromne, D. Poehlau, J. A. Cabrera-Gomez, R. Lucas and H. Butzkueven. Ann Neurol. (Dec 2014) 76(6):880-90. http://dx.doi.org/10.1002/ana.24287

Risk of relapse phenotype recurrence in multiple sclerosis. Kalincik, T., K. Buzzard, V. G. Jokubaitis, M. Trojano, P. Duquette, I. Guillermo, M. Girard, A. Lugaresi, P. Grammond, F. Grand’Maison, C. Oreja-Guevara, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, G. Iuliano, J. Lechner-Scott, M. Barnett, R. Bergamaschi, V. Van Pesch, M. P. Amato, E. van Munster, R. Fernandez-Bolanos, F. Verheul, M. Fiol, E. Cristiano, M. Slee, M. E. Rio, D. L. A. Spitaleri, R. Alroughani, O. Gray, M. L. Saladino, S. Flechter, J. Herbert, J. A. Cabrera- Gomez, N. Vella, M. Paine, C. Shaw, F. Moore, S. Vucic, A. Savino, B. Singhal, T. Pekovska-Boskova, J. Parratt, C-A. Sirbu, C. Rozsa, D. Liew, H. Butzkueven, on behalf of the MSBase study group. Mult Scler. (Oct 2014) 20(11):1511-22. http://dx.doi.org/10.1177/1352458514528762

Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Hughes, S. E., T. Spelman, O. M. Gray, C. Boz, M. Trojano, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. van Pesch, M. P. Amato, G. Iuliano, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolanos, D. Poehlau, M. L. Saladino, N. Deri, J. Cabrera-Gomez, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, G. McDonnell, S. A. Hawkins, F. Kee, H. Butzkueven on behalf of the MSBase study group. Mult Scler. (May 2014) 20(6):739-46. http://dx.doi.org/10.1177/1352458513507816

Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis, V. G., V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, R. Alroughani, J. Lechner-Scott, A. Lugaresi, P. Duquette, M. Girard, M. Barnett, F. Grand’Maison, M. Trojano, M. Slee, G. Giuliani, C. Shaw, C. Boz, D. L. A. Spitaleri, F. Verheul, J. Haartsen, D. Liew, H. Butzkueven on behalf of the MSBase study group. Neurology. (Apr 2014) 82(14):1204-11. http://dx.doi.org/10.1212/WNL.0000000000000283

2013

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Kalincik, T., V. Vivek, V. Jokubaitis, J. Lechner-Scott, M. Trojano, G. Izquierdo, A. Lugaresi, F. Grand’Maison, R. Hupperts, C. Oreja-Guevara, R. Bergamaschi, G. Iuliano, R. Alroughani, V. Van Pesch, M. P. Amato, M. Slee, F. Verheul, R. Fernandez-Bolanos, M. Fiol, D. L. A. Spitaleri, E. Cristiano, O. Gray, J. A. Cabrera-Gomez, V. Shaygannejad, J. Herbert, S. Vucic, M, Needham, T. Petkovska-Boskova, C-A. Sirbu, P. Duquette, M. Girard, P. Grammond, C. Boz, G. Giuliani, M. E. Rio, M. Barnett, S. Flechter, F. Moore, B. Singhal, E. A. Bacile, M. L. Saladino, C. Shaw, E. Skromne, D. Poehlau, N. Vella, T. Spelman, D. Liew, T. J. Kilpatrick, H. Butzkueven on behalf of the MSBase Study Group. Brain. (Dec 2013) 136(Pt 12):3609-17. http://dx.doi.org/10.1093/brain/awt281

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. Kalincik, T., T. Spelman, M. Trojano, P. Duquette, G. Izquierdo, P. Grammond, A. Lugaresi, R. Hupperts, E. Cristiano, V. Van Pesch, F. Grand'Maison, D. La Spitaleri, M. E. Rio, S. Flechter, C. Oreja-Guevara, G. Giuliani, A. Savino, M. P. Amato, T. Petersen, R. Fernandez-Bolanos, R. Bergamaschi, G. Iuliano, C. Boz, J. Lechner-Scott, N. Deri, O. Gray, F. Verheul, M. Fiol, M. Barnett, E. van Munster, V. Santiago, F. Moore, M. Slee, M. L. Saladino, J. Alroughani, C. Shaw, K. Kasa, T. Petkovska- Boskova, L. den Braber-Moerland, J. Chapman, E. Skromne, J. Herbert, D. Poehlau, M. Needham, E. A. Bacile Bacile, W. O. Arruda, M. Paine, B. Singhal, S. Vucic, J. A. Cabrera-Gomez, H. Butzkueven on behalf of the MSBase Study Group. PLoS One. (May 2013) 8(5):e63480. http://dx.doi.org/10.1371/journal.pone.0063480

Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. Iuliano, G., C. Boz, E. Cristiano, P. Duquette, A. Lugaresi, C. Oreja-Guevara and V. Van Pesch. J Neurol. (May 2013) 260(5): 1258-62. http://dx.doi.org/10.1007/s00415-012-6785-y

Fluctuations of MS Births and UV-light exposure. Verheul, F., J. Smolders, M. Trojano, V. Lepore, C. Zwanikken, M. P. Amato, F. Grand'maison, H. Butzkueven, M. Marrosu, P. Duquette, G. Comi, G. Izquierdo, P. Grammond, G. Lus, T. Petersen, R. Bergamaschi, G. Giuliani, C. Boz, G. Coniglio, V. Van Pesch, J. Lechner-Scott, P. Cavalla, F. Granella, C. Avolio, M. Fiol, D. Poehlau, M. L. Saladino, P. Gallo, N. Deri, W. Oleschko Arruda, M. Paine, M. Ferro, M. Barnett, J. A. Cabrera-Gomez, M. Slee, F. Moore, C. Shaw, T. Petkovska-Boskova, M. Rutherford, O. Engelsen, J. Damoiseaux and R. Hupperts. Acta Neurol Scand. (May 2013) 127(5):301-8. http://dx.doi.org/10.1111/ane.12007

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis, V. G., T. Spelman, J. Lechner-Scott, M. Barnett, C. Shaw, S. Vucic, S. Liew, H. Butzkueven, M. Slee on behalf of the Australian MSBase Study Group. PLoS One. (Mar 2013) 8(3):e59694. http://dx.doi.org/10.1371/journal.pone.0059694

2012

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. Trojano, M., G. Lucchese, G. Graziano, B. V. Taylor, S. Simpson, Jr., V. Lepore, F. Grand'Maison, P. Duquette, G. Izquierdo, P. Grammond, M. P. Amato, R. Bergamaschi, G. Giuliani, C. Boz, R. Hupperts, V. Van Pesch, J. Lechner-Scott, E. Cristiano, M. Fiol, C. Oreja-Guevara, M. L. Saladino, F. Verheul, M. Slee, D. Paolicelli, C. Tortorella, M. D'Onghia, P. Iaffaldano, V. Direnzo, H. Butzkueven on behalf of the MSBase Study Group, the New Zealand MS Prevalence Study Group. PLoS One. (Oct 2012) 7(10):e48078. http://dx.doi.org/10.1371/journal.pone.0048078

Increasing age at disability milestones among MS patients in the MSBase registry. Kister, I., E. Chamot, G. Cutter, T. E. Bacon, V. G. Jokubaitis, S. E. Hughes, O. M. Gray, M. Trojano, G. Izquierdo, F. Grand'Maison, P. Duquette, A. Lugaresi, P. Grammond, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, C. Oreja- Guevara, G. Iuliano, J. Lechner-Scott, R. Bergamaschi, M. E. Rio, F. Verheul, M. Fiol, V. Van Pesch, M. Slee, H. Butzkueven, J. Herbert and MSBase Investigators. J Neurol Sci. (Jul 2012) 318(1-2):94-9. http://dx.doi.org/10.1016/j.jns.2012.03.017

The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Lechner-Scott, J., B. Spencer, T. de Malmanche, J. Attia, M. Fitzgerald, M. Trojano, F. Grand'Maison, J. A. C. Gomez, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, C. Boz, G. Giuliani, V. Van Pesch, G. Iuliano, M. Fiol, E. Cristiano, F. Verheul, M. L. Saladino, M. Slee, M. Barnett, N. Deri, S. Flechter, N. Vella, C. Shaw, J. Herbert, F. Moore, T. Petkovska-Boskova, V. Jokubaitis, H. Butzkueven for the MSBase study group. Mult Scler. (Jul 2012) 18(7):974-82. http://dx.doi.org/10.1177/1352458511431729

Country, Sex, Edss Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. Meyniel, C., T. Spelman, V. G. Jokubaitis, M. Trojano, G. Izquierdo, F. Grand'Maison, C. Oreja-Guevara, C. Boz, A. Lugaresi, M. Girard, P. Grammond, G. Iuliano, M. Fiol, J. A. Cabrera-Gomez, R. Fernández Bolaños, G. Giuliani, J. Lechner-Scott, E. Cristiano, J. Herbert, T. Petkovska-Boskova, R. Bergamaschi, V. Van Pesch, F. Moore, N. Vella, M. Slee, V. Santiago, M. Barnett, E. Havrdova, C. Young, C-A. Sirbu, M. Tanner, M. Rutherford, H. Butzkueven, on behalf of the MSBasis Study Group. PLoS One. (Jun 2012) 7(6):e38661. http://dx.doi.org/10.1371/journal.pone.0038661

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase registry. Hughes, S., T. Spelman, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand'Maison, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, R. Bergamaschi, G. Giuliani, M. E. Rio, J. Lechner-Scott, V. van Pesch, G. Iuliano, M. Fiol, F. Verheul, M. Barnett, M. Slee, J. Herbert, I. Kister, N. Vella, F. Moore, T. Petkovska-Boskova, V. Shaygannejad, V. Jokubaitis, G. McDonnell, S. Hawkins, F. Kee, O. Gray, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Mar 2012) 83(3):305-10. http://dx.doi.org/10.1136/jnnp-2011-301051

2006

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Butzkueven, H., J. Chapman, E. Cristiano, F. Grand'Maison, M. Hoffmann, G. Izquierdo, D. Jolley, L. Kappos, T. Leist, D. Pöhlau, V. Rivera, M. Trojano, F. Verheul and J-P. Malkowski. Mult Scler. (Dec 2006) 12(6):769-74. http://dx.doi.org/10.1177/1352458506070775